Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)

Organon

Status and phase: Completed; Phase 3

Conditions: Hypertension

Treatments: Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00400218

2006_049

0954A-323

Details and patient eligibility

About

Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to moderate essential hypertension.

Enrollment: 62 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient is either receiving high blood pressure monotherapy or no treatment
• Patient will have reached the legal age by the time enter the study
• Patients diagnosed with mild to moderate essential high blood pressure or high blood pressure with other conditions such as diabetes or cardiovascular diseases and are taking high blood pressure medication (exclude diuretic), but did not meet treatment goal

Exclusion criteria

• Patient with high levels of uric acid in the blood who has received medications for uric acid in the urine within 3 months prior to enrollment
• Patients who are hypersensitive to any component of the study medication
• Patients who are hypersensitive to other sulfonamide-derived drugs
• Patients with anuria (hyzaar(R) is not recommended for patients with hepatic impairment or severe renal impairment, creatinine clearance </= 30 ml/min)
• Unstable diabetes (hba1c > 8%), or a change in diabetes medication during study treatment. patients with stable diabetes may enter the study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)